JP2023113636A5 - - Google Patents
Info
- Publication number
- JP2023113636A5 JP2023113636A5 JP2023077286A JP2023077286A JP2023113636A5 JP 2023113636 A5 JP2023113636 A5 JP 2023113636A5 JP 2023077286 A JP2023077286 A JP 2023077286A JP 2023077286 A JP2023077286 A JP 2023077286A JP 2023113636 A5 JP2023113636 A5 JP 2023113636A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody polypeptide
- polypeptide
- single variable
- variable domain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511245P | 2017-05-25 | 2017-05-25 | |
| US62/511,245 | 2017-05-25 | ||
| PCT/US2018/034330 WO2018217988A1 (en) | 2017-05-25 | 2018-05-24 | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
| JP2019564951A JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564951A Division JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023113636A JP2023113636A (ja) | 2023-08-16 |
| JP2023113636A5 true JP2023113636A5 (https=) | 2025-11-28 |
Family
ID=62599725
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564951A Pending JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 |
| JP2023077286A Pending JP2023113636A (ja) | 2017-05-25 | 2023-05-09 | 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564951A Pending JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20200148779A1 (https=) |
| EP (1) | EP3630832A1 (https=) |
| JP (2) | JP2020521458A (https=) |
| KR (2) | KR20200012907A (https=) |
| CN (1) | CN110637035A (https=) |
| WO (1) | WO2018217988A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| EP3468997B1 (en) | 2016-06-08 | 2023-09-13 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| WO2018217976A1 (en) | 2017-05-25 | 2018-11-29 | Bristol-Myers Squibb Company | Antagonistic cd40 monoclonal antibodies and uses thereof |
| EP3774902A1 (en) | 2018-04-02 | 2021-02-17 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| CN114599389A (zh) * | 2019-08-22 | 2022-06-07 | 奇达拉治疗公司 | 变体fc结构域及其用途 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| WO2021183428A1 (en) * | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| US20230236199A1 (en) * | 2020-04-23 | 2023-07-27 | Eli Lilly And Company | Subcutaneous absorption and bioavailability of antibodies |
| EP4153630A1 (en) | 2020-05-18 | 2023-03-29 | Bristol-Myers Squibb Company | Antibody variants with improved pharmacokinetic properties |
| CN112552389B (zh) * | 2020-08-07 | 2023-06-06 | 中爱瑞祥(杭州)生物科技有限公司 | 一种活性肽融合蛋白及其制备方法 |
| KR20230097061A (ko) * | 2020-11-02 | 2023-06-30 | 아트라러스, 인크. | Sap fc 융합 단백질 및 사용 방법 |
| AU2022207985A1 (en) | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US9051373B2 (en) * | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| CN103172731A (zh) * | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| KR20080073293A (ko) * | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| BR112013026828A2 (pt) * | 2011-04-21 | 2016-11-29 | Bristol Myers Squibb Co | polipeptídeos de anticorpo que antagonizam cd40 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| WO2015134988A1 (en) * | 2014-03-07 | 2015-09-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| US20170233485A1 (en) * | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| CR20180177A (es) * | 2015-09-30 | 2018-06-22 | Janssen Biotech Inc | Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso |
| WO2018217976A1 (en) * | 2017-05-25 | 2018-11-29 | Bristol-Myers Squibb Company | Antagonistic cd40 monoclonal antibodies and uses thereof |
-
2018
- 2018-05-24 KR KR1020197037759A patent/KR20200012907A/ko not_active Ceased
- 2018-05-24 WO PCT/US2018/034330 patent/WO2018217988A1/en not_active Ceased
- 2018-05-24 US US16/495,994 patent/US20200148779A1/en not_active Abandoned
- 2018-05-24 JP JP2019564951A patent/JP2020521458A/ja active Pending
- 2018-05-24 CN CN201880032964.0A patent/CN110637035A/zh active Pending
- 2018-05-24 KR KR1020247019564A patent/KR102847736B1/ko active Active
- 2018-05-24 EP EP18731284.8A patent/EP3630832A1/en active Pending
-
2023
- 2023-05-09 JP JP2023077286A patent/JP2023113636A/ja active Pending
-
2025
- 2025-08-28 US US19/313,261 patent/US20260042858A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023113636A5 (https=) | ||
| US10442857B2 (en) | Anti-IL-17 antibodies | |
| ES2569217T3 (es) | Agente para tratar enfermedades | |
| JP2020184996A5 (https=) | ||
| US7179465B2 (en) | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon | |
| JP2020525032A5 (https=) | ||
| JP2020521458A5 (https=) | ||
| JP2020193210A5 (https=) | ||
| JP2014530611A5 (https=) | ||
| JP2017099391A5 (https=) | ||
| ME00519B (me) | Antitijela visokog afiniteta prema humanom il-6 receptoru | |
| JP2023120208A5 (https=) | ||
| JP7680078B2 (ja) | 抗ヒトインターフェロンα受容体１モノクローナル抗体及びその使用 | |
| JP2010500005A5 (https=) | ||
| JP2020532285A5 (https=) | ||
| CN106102837A (zh) | 经由细胞受体锚定使用具有天然架构的双特异性抗体改良的hiv‑1‑中和抗体效力和广度 | |
| KR20070020048A (ko) | 항체 | |
| KR20240029115A (ko) | 개선된 ｔｎｆ 결합제 | |
| KR20140108520A (ko) | CD1d에 대한 항체 | |
| Vance et al. | Resolution of two overlapping neutralizing B cell epitopes within a solvent exposed, immunodominant α-helix in ricin toxin's enzymatic subunit | |
| CN112105373A (zh) | 治疗b型肝炎病毒感染的方法 | |
| TW202320782A (zh) | 癌症治療組合 | |
| CA3197642A1 (en) | Polypeptides targeting sars-cov-2 and related compositions and methods | |
| WO2023185957A1 (zh) | 抗体、融合蛋白及其用途 | |
| JPWO2020106620A5 (https=) |